Phenotypes Associated with This Genotype

Genotype
MGI:5634289

• Allelic Composition: Tg(Scgb1a1-rtTA)1Jaw/0; Tg(tetO-EGFR*L858R)#Hev/0
• Genetic Background: involves: 129 * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased lung adenocarcinoma incidence ( J:128700 , J:213447 )

• tumor bearing mice treated with the geldanamycin analogue, 17-AAG, which inhibits Hsp90, show a transient degeneration of tumors (J:128700)

• mice treated with doxycycline develop lung adenocarcinomas (J:213447)

• mice treated with doxycycline, followed by treatment with a tyrosine kinase inhibitor erlotinib, initially show tumor regression but eventually develop tumors resistant to long-term erlotinib treatment (J:213447)

• treatment of doxycycline treated mice that have erlotinib-resistant tumors with a MEK inhibitor, trametinib, results in tumor regression (J:213447)

• treatment of doxycline treated mice with trametinib alone does not have an effect on tumor growth (J:213447)

respiratory system

increased lung adenocarcinoma incidence ( J:128700 , J:213447 )

• tumor bearing mice treated with the geldanamycin analogue, 17-AAG, which inhibits Hsp90, show a transient degeneration of tumors (J:128700)

• mice treated with doxycycline develop lung adenocarcinomas (J:213447)

• mice treated with doxycycline, followed by treatment with a tyrosine kinase inhibitor erlotinib, initially show tumor regression but eventually develop tumors resistant to long-term erlotinib treatment (J:213447)

• treatment of doxycycline treated mice that have erlotinib-resistant tumors with a MEK inhibitor, trametinib, results in tumor regression (J:213447)

• treatment of doxycline treated mice with trametinib alone does not have an effect on tumor growth (J:213447)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:128700 , J:213447